How Does Polivy Compare to Other Treatments for Lymphoma?
Polivy (polatuzumab vedotin), an antibody-drug conjugate from Genentech, targets CD79b on B-cells and is FDA-approved with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated diffuse large B-cell lymphoma (DLBCL). It improves progression-free survival (PFS) over standard R-CHOP in frontline therapy.[1]
Polivy-R-CHP vs. R-CHOP in Frontline DLBCL
In the phase 3 POLARIX trial, Polivy-R-CHP reduced disease progression or death risk by 27% compared to R-CHOP (HR 0.73; 95% CI 0.57-0.95) at 28 months median follow-up. Two-year PFS was 76.7% vs. 70.4%; overall survival showed no significant difference yet (HR 0.90).[1][2] Peripheral neuropathy occurred more often with Polivy (40.7% any grade vs. 33.9%), but cardiac toxicity was similar.
How Does It Stack Up Against CAR-T Therapies Like Yescarta or Breyanzi?
CAR-T cells (axicabtagene ciloleucel/Yescarta, lisocabtagene maraleucel/Breyanzi) are second-line options post-relapse for transplant-ineligible DLBCL patients. They offer higher complete response rates (50-60% vs. Polivy's frontline setting) but require specialized centers, carry cytokine release syndrome/boxyth release syndrome risks (up to 90%), and cost $400,000+ per treatment. Polivy-R-CHP is frontline, outpatient, and cheaper (~$150,000/course), with ZUMA-7 data showing Yescarta's PFS benefit (HR 0.398) over standard chemo but higher toxicity.[3][4]
| Treatment | Setting | 2-Year PFS | Key Risks | Approx. Cost |
|-----------|---------|------------|-----------|--------------|
| Polivy-R-CHP | Frontline | 77% | Neuropathy (41%) | $150K |
| R-CHOP | Frontline | 70% | Cardiac (similar) | $100K |
| Yescarta (CAR-T) | 2nd-line | 41-65% | CRS/neurotoxicity (90%) | $425K |
| Breyanzi (CAR-T) | 2nd-line | 56% | CRS (45%) | $410K |
Comparison with Other DLBCL Targeted Therapies
- Vs. Rituxan (rituximab) monotherapy or combos: Polivy adds conjugate cytotoxicity, outperforming rituximab-based regimens in relapsed settings (ORR 45% vs. 20-30%).[5]
- Vs. Brukinsa (zanubrutinib) or Jaypirca (pirtobrutinib): BTK inhibitors excel in relapsed/refractory (ORR 70-80%) but lack head-to-head frontline data; Polivy suits earlier use.[6]
- Vs. Epkinly (epcoritamab): Bispecific T-cell engager shows 63% ORR in relapsed DLBCL (EPCORE NHL-1), subcutaneous dosing, but higher infection rates (CRS 57%). No direct comparison; Epkinly is post-two-lines.[7]
When Is Polivy Preferred Over Alternatives?
Guidelines (NCCN) recommend Polivy-R-CHP as category 1 frontline for transplant-ineligible patients or high-risk IPI scores, especially avoiding vincristine-related neuropathy. CAR-T or bispecifics follow for relapse. Real-world data confirm PFS gains hold across ages, though elderly patients (>80) see attenuated benefits.[2][8]
Patent and Pricing Context
Polivy's composition of matter patent (US 8,153,768) expires in 2027, with formulation patents to 2034; no major challenges listed. U.S. list price ~$38,500/dose (6 doses/course). Biosimilars unlikely before 2030 due to conjugates' complexity.[9]
[1] NEJM: POLARIX trial (2022) - https://www.nejm.org/doi/full/10.1056/NEJMoa2115304
[2] Lancet Haematol: Updated POLARIX (2023) - https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00152-8/fulltext
[3] NEJM: ZUMA-7 (2022) - https://www.nejm.org/doi/full/10.1056/NEJMoa2116133
[4] TRANSCEND NHL 001 (Breyanzi) - https://www.nejm.org/doi/full/10.1056/NEJMoa2209420
[5] Polivy prescribing info - https://www.gene.com/download/pdf/polivy_prescribing.pdf
[6] NCCN DLBCL Guidelines v.5.2024
[7] EPCORE NHL-1 (Epkinly) - https://www.nejm.org/doi/full/10.1056/NEJMoa2301457
[8] JCO: Real-world POLARIX (2024)
[9] DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/POLIVY